Boston Scientific Q4 Earnings Disappoint, Shares Plummet 16% Despite Solid Growth

Boston Scientific's Q4 earnings beat expectations, with 16% sales and 14% EPS growth. However, the company missed Q1 and 2026 guidance by a penny, causing a 16% stock price drop. Despite this, the company delivered 18% sales growth in its cardiovascular segment and 12% in its medsurg unit, with a projected 11.25% sales growth in 2026. The stock is trading at 28 times forward FCF and has a history of innovation and investment.